Investor · 2 deals
Every published round MRCF-BTF took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Denteric | Series A | 26 Sep 2019 | $14m | Participant | Startup Daily (Fri 4 Oct 2019), @AuManufacturing, Brandon BioCatalyst portfolio, Brandon Capital portfolio, Startup Daily (Thu 26 Sep 2019), denteric.com (undated), denteric.com (undated), Brandon Capital portfolio | |
| Respirion | Unnamed stage | 21 Mar 2019 | ≤$20m | Lead | @AuManufacturing, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Companies MRCF-BTF has backed in a published round, and companies whose existing shares it bought off another holder.
Fund closes reported for MRCF-BTF, as distinct from the investments it has made.
Companies MRCF-BTF has backed that another company then bought. An exit for the holding, not a deal MRCF-BTF did.
Stories naming MRCF-BTF. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The MRCF Biomedical Translation Fund has launched Respirion Pharmaceuticals, a Perth biotech developing an inhaled antibiotic for cystic fibrosis, committing up to A$20 million, with up to US$3 million from the CF Foundation.